Polyphor Ltd says it will proceed alone with Phase II testing of its macrocycle antibiotic candidate POL7080 after Roche Holdings AG decided it would take too long to develop the investigational drug for treating patients with severe Pseudomonas aeruginosa infections, and so handed it back to the Swiss biotech.
Roche, which announced the partnership with Polyphor in November 2013, said in July it had removed RG7929 (POL7080) from Phase...